CeGaT Revolutionizes Exome Diagnostics with Genome-wide CNV Analysis
CeGaT, a global provider of genetic diagnostics and sequencing services, presents an innovation in exome diagnostics: Wi…
CeGaT, a global provider of genetic diagnostics and sequencing services, presents an innovation in exome diagnostics: Wi…
Molecular Health (MH), ein international tätiges Biotech-IT-Unternehmen aus Heidelberg, das auf Basis seiner proprietäre…
Univ.-Prof. Dr. rer. nat. Axel Hillmer, Leiter der Genomischen Pathologie an der Uniklinik Köln und der Medizinischen Fa…
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QIAGEN Clinical Insight (QCI®), its clinical dec…
CeGaT GmbH, a leading global genetic testing provider focused on large panel and trio-exome diagnostics, has obtained it…
With the upcoming release of CentoMD® 3.1 end of September 2016, CENTOGENE will report genetic information and clinical…
Collaboration between FDNA, the developer of the Face2Gene Suite and CENTOGENE, worldwide leader in genetic diagnostics,…
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) und die CENTOGENE AG gaben heute eine Vereinbarung über die gemeins…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung von drei innovativen „Sample to Insight…
CENTOGENE AG (“CENTOGENE”) announces the launch of the completely updated CentoMD® 3.0 CentoMD®, the world’s leading pr…